Business
Ventripoint to Present its AI-enhanced Cardiac Ultrasound Technology to B.C. and Canadian Health Care Leaders at The Data Effect
(TheNewswire) Toronto, Ontario – TheNewswire - June 24, 2024 – ...
About this update from Ventripoint Diagnostics Ltd.
[{"type":"text","content":"Ventripoint to Present its AI-enhanced Cardiac Ultrasound Technology to B.C. and Canadian Health Care Leaders at The Data Effect\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Toronto, Ontario –\n \n \n TheNewswire -\n \n \n June 24, 2024\n \n \n –\n \n \n Ventripoint Diagnostics Ltd.\n \n \n (\"Ventripoint\"\n \n or the\n \n \"Company\"),\n(TSXV:VPT\n \n \n )\n \n \n ;\n \n \n (\n \n \n OTC:VPTDF)\n \n has been\nselected to present its AI-enhanced cardiac ultrasound technology,\nwhich generates MRI-quality cardiac measurements in minutes, to\nhealth-care leaders at The Data Effect on June 25\n \n th\n \n in Vancouver.\n \n \n CEO Hugh MacNaught will be on the panel\n \n Accelerating AI Startups\nin Canadian Health Care\n \n \n , which explores\napplications of AI and digital health with global impact.\n \n \n \n \n He is being joined on this panel at\n \n \n \n \n The Data\nEffect\n \n \n \n \n by other health care leaders,\nincluding: Maryam Sadeghi PhD, CEO & Co-Founder of MetaOptima;\nLloyd Jura, a Professor specializing in AI and cybersecurity at New\nYork Institute of Technology; Tiffany Chiu, AbCellera’s\nVice-President of Communications; and the Vancouver-based innovator\nDr. Alexandra T Greenhill, CEO of CareTeam Technologies.\n \n \n \n “This is an important forum to meet the innovators as well as the\nhealth care and hospital thought leaders who are at the lead of\nbringing new approaches to data and AI to provincial health care\nsystems,” said MacNaught. “We are delighted to have been invited\nto The Data Effect, as we introduce Ventripoint innovations to\nhospitals around Canada and the world.”\n \n \n Ventripoint’s VMS+ easily interfaces with all major brands of\nechocardiography machines and transforms 2D ultrasound scans into 3D\nimages of all four chambers of the heart more rapidly and at less\nexpense than cardiac MRI. VMS+ has received clearance by FDA, and is\nlicensed for sale by Health Canada and regulators in the UK and EU. It\nis now being used in leading hospitals in Canada, the US, Germany and\nthe UK.\n \n \n The Data Effect has been gathering Canada’s health care leaders\ntogether for more than a decade, to highlight ...